Cargando…

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma

For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Xiaoyu, Zheng, Qiwen, Yang, Lu, Zhu, Yixiang, Li, Junling, Liu, Yutao, Wang, Ziping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431114/
https://www.ncbi.nlm.nih.gov/pubmed/28469143
http://dx.doi.org/10.1038/s41598-017-01347-6
_version_ 1783236368224223232
author Zhai, Xiaoyu
Zheng, Qiwen
Yang, Lu
Zhu, Yixiang
Li, Junling
Liu, Yutao
Wang, Ziping
author_facet Zhai, Xiaoyu
Zheng, Qiwen
Yang, Lu
Zhu, Yixiang
Li, Junling
Liu, Yutao
Wang, Ziping
author_sort Zhai, Xiaoyu
collection PubMed
description For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation of best matched pairs for the two categories. DFS was proved to be considerably better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was found to be associated with lower rates of several hematological and non-hematological adverse events (AEs), when compared with gemcitabine containing chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less clinical toxicity in comparison with non-pemetrexed based doublets.
format Online
Article
Text
id pubmed-5431114
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-54311142017-05-16 Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma Zhai, Xiaoyu Zheng, Qiwen Yang, Lu Zhu, Yixiang Li, Junling Liu, Yutao Wang, Ziping Sci Rep Article For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation of best matched pairs for the two categories. DFS was proved to be considerably better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was found to be associated with lower rates of several hematological and non-hematological adverse events (AEs), when compared with gemcitabine containing chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less clinical toxicity in comparison with non-pemetrexed based doublets. Nature Publishing Group UK 2017-05-03 /pmc/articles/PMC5431114/ /pubmed/28469143 http://dx.doi.org/10.1038/s41598-017-01347-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhai, Xiaoyu
Zheng, Qiwen
Yang, Lu
Zhu, Yixiang
Li, Junling
Liu, Yutao
Wang, Ziping
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_full Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_fullStr Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_full_unstemmed Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_short Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
title_sort impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431114/
https://www.ncbi.nlm.nih.gov/pubmed/28469143
http://dx.doi.org/10.1038/s41598-017-01347-6
work_keys_str_mv AT zhaixiaoyu impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
AT zhengqiwen impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
AT yanglu impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
AT zhuyixiang impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
AT lijunling impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
AT liuyutao impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma
AT wangziping impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma